一线慢性淋巴细胞白血病中的终点替代性
该研究通过患者水平和试验水平分析,评估一线慢性淋巴细胞白血病(CLL)试验中无进展生存期(PFS)和微小残留病(MRD)与总生存期(OS)的相关性。患者水平分析纳入12项德国CLL研究组(GCLLSG)试验的4,237例患者,并在靶向治疗(TT)中验证相关性;Meta分析纳入2008至2024年一线III期试验的8,065例患者。结论指出,在TT背景下患者水平相关性得到确认,而PFS与OS的治疗效应相关性仍不确定;MRD缓解状态与PFS的治疗效应相关性高,但与OS相关性不高,且可用的MRD数据随机试验数量有限。
要点
- 患者水平PFS与OS相关性在靶向治疗中强(tau 0.91),在化疗/化学免疫治疗中弱(tau 0.52)。
- Meta分析中PFS与OS的风险比治疗效应相关性为R=0.75(95%CI 0.74-0.76,R²=0.56)。
- 治疗结束时MRD与PFS治疗效应相关性R=0.88,与OS相关性R=0.71,但可用MRD数据的随机试验数量有限。
核心结论
- 在靶向治疗背景下患者水平PFS与OS相关性得到确认,而PFS与OS的治疗效应相关性仍不确定。
- MRD缓解状态与PFS的治疗效应相关性高,但与OS相关性不高,且可用的MRD数据随机试验数量有限。
研究设计与样本
- 患者水平分析使用12项德国CLL研究组(GCLLSG)一线试验的源数据,并拟合联合脆弱Copula模型在靶向治疗(TT)中验证相关性。
- Meta分析纳入2008至2024年一线III期CLL试验,从7项GCLLSG试验和9项已发表试验量化治疗效应相关性。
主要发现
- GCLLSG分析集包含4,237例患者,患者水平PFS/OS相关性Spearman Rho>0.9。
- 联合脆弱Copula模型显示化疗/化学免疫治疗(C/CIT)相关性弱,tau为0.52(95%CI 0.49-0.55);靶向治疗(TT)相关性强,tau为0.91(95%CI 0.89-0.93)。
- Meta分析集共8,065例患者,其中5,198例(64%)接受C/CIT,2,867例(36%)接受TT。
- PFS与OS的风险比治疗效应相关性为R=0.75(95%CI 0.74-0.76,R²=0.56)。
- 治疗结束时MRD与PFS和OS的治疗效应相关性分别为R=0.88(95%CI -0.87至0.89;R²=0.78)和R=0.71(95%CI 0.69-0.73;R²=0.5)。
局限性
- 可用的MRD数据随机试验数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Surrogate end points are commonly used to estimate treatment efficacy in clinical studies of chronic lymphocytic leukemia (CLL). This patient- and trial-level analysis describes the correlation between progression-free survival (PFS) and minimal residual disease (MRD) with overall survival (OS) in first-line trials for CLL. PATIENTS AND METHODS: First, patient-level correlation was confirmed using source data from 12 frontline German CLL Study Group (GCLLSG)-trials. Additionally, a joint-frailty copula model was fitted to validate correlation in the setting of targeted therapies (TT). Second, a meta-analysis of first-line phase III trials in CLL from 2008 to 2024 was performed. Treatment effect correlation was quantified from seven GCLLSG and nine published trials, using hazard ratios (HRs) for time-to-event and odds ratios for binary end points. RESULTS: The GCLLSG analysis set comprised 4,237 patients. Patient-level correlation for PFS/OS was strong with Spearman Rho >0.9. The joint-frailty copula indicated a weak correlation for chemotherapy/chemoimmunotherapy (C/CIT) with a tau of 0.52 (95% CI, 0.49 to 0.55) while the correlation was strong for TT (tau, 0.91 [95% CI, 0.89 to 0.93). The meta-analysis set contained a total of 8,065 patients including 5,198 (64%) patients treated with C/CIT and 2,867 (36%) treated with TT. Treatment-effect correlation of the HRs for PFS and OS was R = 0.75 (95% CI, 0.74 to 0.76, R2 = 0.56) while correlation of end-of-treatment MRD with PFS and OS was R = 0.88 (95% CI, -0.87 to 0.89; R2 = 0.78) and 0.71 (95% CI, 0.69 to 0.73; R2 = 0.5), respectively. CONCLUSION: Patient-level correlation was confirmed in the setting of TTs while treatment-effect correlation between PFS and OS remains uncertain. MRD response status showed a high treatment-effect correlation with PFS but not OS, with the caveat of a limited number of randomized trials with available MRD data.
引用
- Simon F, Ligtvoet R, Robrecht S, et al. End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. J Clin Oncol. 2024. PMID: 39213466. doi:10.1200/JCO.24.01192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。